Free Versus Fixed-Ratio Combination of Basal Insulin and GLP-1 Receptor Agonists in Type 2 Diabetes Uncontrolled With GLP-1 Receptor Agonists: A Systematic Review and Indirect Treatment Comparison

Overview of attention for article published in Frontiers in endocrinology, May 2022

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 21 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 7 publications that cite this research output.

7

The most recent citing publications are shown below. View all 7 publications that cite this research output on Dimensions.

Efficacy of a fixed-ratio combination of glucagon-like peptide-1 receptor agonist and basal insulin therapy for the treatment of type 2 diabetes: a protocol for systematic review and meta-analysis of randomized clinical trials

Preprint in medRxiv (July 2024)

Comparation of fixed‐ratio (IDegLira and iGlarLixi) versus free combination of basal insulin and glucagon‐like peptide‐1 receptor agonist for uncontrolled type 2 diabetes: A systematic review and network meta‐analysis

Article in Journal of Evidence-Based Medicine (June 2024)

Treatment intensification following glucagon-like peptide-1 receptor agonist in type 2 diabetes: Comparative effectiveness analyses between free vs. fixed combination of GLP-1 RA and basal insulin. RESTORE-G real-world study

Article in Nutrition Metabolism and Cardiovascular Diseases (March 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.